We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+8.48%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$4.36M
Cap. Flow
-$1.35M
Cap. Flow %
-1.28%
Top 10 Hldgs %
48.69%
Holding
48
New
6
Increased
14
Reduced
19
Closed
7

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.61M
2
ONC
BeOne Medicines Ltd
ONC
+$2.1M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$1.98M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$1.96M
5
LEXEA
Liberty Expedia Holdings, Inc. Class A Common Stock
LEXEA
+$1.6M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$2.46M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.97M
3
NKTR icon
Nektar Therapeutics
NKTR
+$1.87M
4
ALSN icon
Allison Transmission
ALSN
+$1.77M
5
TGTX icon
TG Therapeutics
TGTX
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Financials 35.38%
3 Technology 6.18%
4 Energy 4.96%
5 Consumer Discretionary 4.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.06T
$29.2M 27.59%
117
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.36B
$3.15M 2.98%
+375,348
New +$2.61M
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.83M 2.68%
37,283
+7,502
+25% +$464K
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$2.44M 2.3%
224,820
+46,979
+26% +$476K
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$2.42M 2.28%
76,851
+12,704
+20% +$376K
ARDX icon
6
Ardelyx
ARDX
$1.28B
$2.4M 2.26%
189,477
+50,120
+36% +$660K
INCY icon
7
Incyte
INCY
$23.4B
$2.35M 2.22%
17,593
-3,008
-15% -$383K
ASND icon
8
Ascendis Pharma A/S
ASND
$17.1B
$2.34M 2.2%
83,411
-21,382
-20% -$540K
DBVT
9
DBV Technologies
DBVT
$870M
$2.21M 2.09%
6,288
+462
+8% +$162K
RARX
10
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.21M 2.08%
+103,606
New +$1.98M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$2.18M 2.06%
34,652
+5,051
+17% +$315K
ONC
12
BeOne Medicines Ltd
ONC
$32.4B
$2.11M 1.99%
+57,654
New +$2.1M
SMC
13
Summit Midstream
SMC
$407M
$2.1M 1.98%
5,837
– –
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.09M 1.97%
23,791
+744
+3% +$66.2K
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
$2.05M 1.93%
486,438
+32,336
+7% +$134K
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.03M 1.92%
16,461
+6,939
+73% +$909K
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
$2.03M 1.92%
16,753
-904
-5% -$117K
WVE icon
18
Wave Life Sciences
WVE
$1.12B
$2.02M 1.91%
73,543
+17,469
+31% +$488K
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.38B
$1.93M 1.82%
56,135
-19,986
-26% -$705K
NGNE icon
20
Neurogene
NGNE
$744M
$1.87M 1.77%
5,603
-1,582
-22% -$556K
AWI icon
21
Armstrong World Industries
AWI
$6.66B
$1.85M 1.75%
40,276
+247
+0.6% +$10.5K
LSXMK
22
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
$1.77M 1.67%
59,960
+440
+0.7% +$12.4K
BFH icon
23
Bread Financial
BFH
$4.01B
$1.77M 1.67%
8,888
-803
-8% -$152K
VISN
24
Vistance Networks Inc
VISN
$2.74B
$1.75M 1.65%
41,872
-4,602
-10% -$177K
TFCF
25
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
$1.72M 1.63%
54,202
-5,112
-9% -$154K
1
2

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q1 2017 Portfolio in Review

As of Q1 2017, Emory University held 48 positions worth $106M, up 4.3% from $102M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Emory University's Q1 2017 filing shows 6 new, 14 increased, 19 reduced and 7 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 375,348 shares worth $3.15M. The largest sale was Aclaris Therapeutics, an estimated $2.46M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 37% a quarter earlier, followed by Financials and Technology.

  • Emory University's largest Q1 2017 buy was BioCryst Pharmaceuticals: 375,348 shares worth $3.15M.
  • Emory University added most to Bellicum Pharmaceuticals, Inc. in Q1 2017, an estimated $909K increase.
  • Emory University's biggest Q1 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $705K.
  • Emory University fully exited Aclaris Therapeutics in Q1 2017, selling an estimated $2.46M.
  • Emory University's ten largest holdings make up 49% of its $106M portfolio in Q1 2017.
  • Emory University opened 6 new positions and closed 7 in Q1 2017.
  • Emory University's portfolio value rose 4.3% quarter-over-quarter to $106M.

Based on Emory University's 13F filing for Q1 2017, filed 11 May 2017.